John G. Gribben
Queen Mary University of London
662 Papers
4.8K Citations
John G. Gribben is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Chronic lymphocytic leukemia & Medicine. The author has an hindex of 46, co-authored 612 publications. Previous affiliations of John G. Gribben include University of London & University of California, Los Angeles.
Chat about Author
Papers
Depletion of CLL-associated patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo.
Bola S. Hanna,Fabienne McClanahan,Haniyeh Yazdanparast,Nadja Zaborsky,Verena Kalter,Philipp M Rößner,Axel Benner,Claudia Dürr,Alexander Egle,John G. Gribben,Peter Lichter,Martina Seiffert +11 more
TL;DR: In vivo myeloid cell depletion using liposomal Clodronate resulted in a significant control of CLL development accompanied by a pronounced repair of innate immune cell phenotypes and a partial resolution of systemic inflammation.
HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era
Silvia Montoto,Kate Shaw,Jessica Okosun,Shreyans Gandhi,Paul Fields,Andrew D. Wilson,Milensu Shanyinde,Kate Cwynarski,Robert Marcus,Johannes de Vos,Anna Marie Young,Melinda Tenant-Flowers,Chloe Orkin,Margaret A. Johnson,Daniella Chilton,John G. Gribben,Mark Bower +16 more
TL;DR: It is demonstrated that HIV-positive patients with HL have more extensive disease with more adverse prognostic factors than HIV-negative patients, but when treated with ABVD, HIV infection does not adversely affect OS or EFS.
Long-Term Follow-up of Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia: Prognostic Model to Predict Outcome
Jennifer R. Brown,Jennifer R. Brown,Haesook T. Kim,Philippe Armand,Philippe Armand,Corey Cutler,Corey Cutler,David C. Fisher,David C. Fisher,Vincent T. Ho,Vincent T. Ho,John Koreth,John Koreth,Jerome Ritz,Jerome Ritz,Catherine J. Wu,Catherine J. Wu,Joseph H. Antin,Joseph H. Antin,Robert J. Soiffer,Robert J. Soiffer,John G. Gribben,John G. Gribben,Edwin P. Alyea,Edwin P. Alyea +24 more
TL;DR: It is concluded that RIC HSCT for CLL in the current era is associated with excellent long-term PFS and OS, and, as potentially curative therapy, should be considered early in the disease course of relapsed high-risk CLL patients.
5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
Susan O'Brien,Joseph O. Moore,Thomas E. Boyd,Loree Larratt,Aleksander B. Skotnicki,Benjamin Koziner,Asher Chanan-Khan,John F. Seymour,John G. Gribben,Loretta M. Itri,Kanti R. Rai +10 more
TL;DR: In relapsed/refractory CLL, OBL combined with FC offers patients who achieve complete or partial remission, as well as those who have fludarabine-sensitive disease, a significant survival benefit.
Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations
John Riches,Conor J. O’Donovan,Sarah J. Kingdon,Fabienne McClanahan,Andrew Clear,Donna Neuberg,Lillian Werner,Carlo M. Croce,Alan G. Ramsay,Laura Z. Rassenti,Thomas J. Kipps,John G. Gribben +11 more
TL;DR: Trisomy 12 CLL cells exhibit functional upregulation of integrin signaling, with β2-integrin expression being modulated by NOTCH1 mutation status, resulting in enhanced very late antigen-4 [VLA-4] directed adhesion and motility.